Connor, Clark & Lunn Investment Management (CC&L)
SYRE icon

Connor, Clark & Lunn Investment Management (CC&L)’s Spyre Therapeutics SYRE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-646
Closed -$149K – 1115
2020
Q2 		$149K Buy
+646
New +$123K ﹤0.01% 926

Other funds holding SYRE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SYRE Position: Q3 2020 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Spyre Therapeutics (SYRE) in Q3 2020, closing a stake of 646 shares — an estimated $149K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SYRE in Q2 2020 and held it in 1 quarter. The position peaked at $149K in Q2 2020. 94 funds tracked by Wall St. Rank hold SYRE as of Q3 2020.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Spyre Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 646 Spyre Therapeutics shares in Q3 2020, an estimated $149K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Spyre Therapeutics in Q2 2020 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Spyre Therapeutics position peaked at $149K in Q2 2020.
  • 94 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2020.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2020, filed 12 Nov 2020.